Latest News
In Vivo CAR-T Is Shifting the Engineering Challenge Into Delivery
CAR T-cell therapy is revolutionizing cancer treatment and being applied to a variety of other indications, but the approach relies on engineering a patient’s immune cells to recognize and attack cancer. Producing those cells can involve a complex, resource- and...
Latest News
Weekly News Roundup | 2 November 2026
Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...
ESMO 2026: The Five Results That Could Change Cancer Treatment
ESMO 2026 closed in Madrid on 27 October after five days of practice-shaping data. The most closely watched results came in three Presidential Symposia, which carried twelve late-breaking phase 3 trials. Five of them stand out for their potential to change how...
What Are You Signing When the AI Wrote the Note?
Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...
Peptide Compounding Explained: What the HHS Six-Peptide Policy Allows
Peptide compounding in the United States has entered a new phase. The Department of Health and Human Services (HHS) will not act against compounders of six unapproved peptides, within strict conditions. The peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
An AI Study Without Its Data Is Fiction
Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...
Weekly News Roundup | 19 October 2026
Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...
FDA Rare Disease Framework: What Will It Change for Developers?
The FDA rare disease framework has not yet changed any rule or approval standard. The agency announced it on 14 October 2026 as an initiative, backed by a white paper. It promises evidence expectations tailored to each rare disease, but it sets no timetable. A public...
Clinical Trial Results 16 October 2026
The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...
In Vivo Gene Editing Nears Its First FDA Decision: What the Data Shows
In vivo gene editing now has a fixed regulatory date. In April 2026, Intellia Therapeutics reported Phase 3 results for lonvo-z, a therapy that edits DNA inside the body. The company described the result as a global first for in vivo gene editing. In September, the US...
Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?
Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence for BCG-unresponsive bladder cancer. However, NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence. The question matters again because of a US...
Cresset’s Flare AI Client Turns Hours of Work into Minutes
Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours. CAMBRIDGE, UK, 6 October 2026 Drug discovery...
The National Priority Voucher: Inside the FDA’s Shortest Review Pathway
Last updated: 15 October 2026. Programme facts checked against FDA sources on that date. A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather...
Bispecific T-Cell Engagers in Refractory Autoimmune Disease
Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...
Icotrokinra NHS Access: Will the Oral Psoriasis Pill Reach Patients?
Icotrokinra NHS access has no published timetable. As of 14 October 2026, LSDN searches found no UK marketing authorisation for icotrokinra. The drug is approved as Icotyde in the US and EU. The European Commission authorisation was announced on 21 September 2026....
When Familiar Is Not Documented: Mandatory GRAS and Traditional Botanicals
Longan was a familiar food in the home I grew up in. It was a tasty summer fruit we ate in southern China, much like an American family might think of mango. Years later, when I started making beverages in St. Louis, I used longan in a hydration drink, well before FDA...
Medicine Does Not Run on Blood Alone
Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...
An AI Study Without Its Data Is Fiction
Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...
Weekly News Roundup | 19 October 2026
Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...
FDA Rare Disease Framework: What Will It Change for Developers?
The FDA rare disease framework has not yet changed any rule or approval standard. The agency announced it on 14 October 2026 as an initiative, backed by a white paper. It promises evidence expectations tailored to each rare disease, but it sets no timetable. A public...
Clinical Trial Results 16 October 2026
The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...
In Vivo Gene Editing Nears Its First FDA Decision: What the Data Shows
In vivo gene editing now has a fixed regulatory date. In April 2026, Intellia Therapeutics reported Phase 3 results for lonvo-z, a therapy that edits DNA inside the body. The company described the result as a global first for in vivo gene editing. In September, the US...
Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?
Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence for BCG-unresponsive bladder cancer. However, NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence. The question matters again because of a US...
Cresset’s Flare AI Client Turns Hours of Work into Minutes
Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours. CAMBRIDGE, UK, 6 October 2026 Drug discovery...
The National Priority Voucher: Inside the FDA’s Shortest Review Pathway
Last updated: 15 October 2026. Programme facts checked against FDA sources on that date. A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather...
Bispecific T-Cell Engagers in Refractory Autoimmune Disease
Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...
Icotrokinra NHS Access: Will the Oral Psoriasis Pill Reach Patients?
Icotrokinra NHS access has no published timetable. As of 14 October 2026, LSDN searches found no UK marketing authorisation for icotrokinra. The drug is approved as Icotyde in the US and EU. The European Commission authorisation was announced on 21 September 2026....
When Familiar Is Not Documented: Mandatory GRAS and Traditional Botanicals
Longan was a familiar food in the home I grew up in. It was a tasty summer fruit we ate in southern China, much like an American family might think of mango. Years later, when I started making beverages in St. Louis, I used longan in a hydration drink, well before FDA...
Medicine Does Not Run on Blood Alone
Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...
Featured Articles
Further News
ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?
Several companies are now developing ALK7 obesity drugs, but human data remain early. On 13 October 2026, Rona Therapeutics licensed an ALK7-targeting RNAi candidate to Roche. Arrowhead, and SiranBio with GSK, have also disclosed ALK7 programmes. Fierce Biotech...
What Pharma Can Learn From Retail as GLP-1 Demand Reshapes Healthcare
Demand for weight-loss medicines in the UK has run well ahead of what the NHS can provide. Researchers at UCL estimate that 1.6 million adults in Great Britain used a medicine to lose weight between early 2024 and early 2025, and that a further 3.3 million were...
Admilparant Approval: What the ALOFT-IPF Result Shows So Far
Admilparant approval for idiopathic pulmonary fibrosis (IPF) is not yet decided, and LSDN found no announced regulatory filing. On 12 October 2026, Bristol Myers Squibb (BMS) reported that its phase 3 ALOFT-IPF trial met its primary endpoint. That was at the 60 mg...
AI Can Accelerate Optimisation, But It Cannot Replace Biological Discovery
Artificial intelligence is increasingly being integrated into the drug discovery process. From the identification of therapeutic targets to the prediction of molecular interactions and ranking of compounds to be developed further, the power of computational tools...
Why Women’s Health Innovation Needs Commercialisation Strategy
Women’s health innovation is experiencing a period of rapid growth. Founders are developing new diagnostics, medical devices, digital platforms, wearables and therapies for conditions that have historically received too little research attention and investment. That...
A Regulatory Playbook for SaMD and Digital Health
Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...
Beyond Binding: Functional Prediction in GPCR Drug Discovery
In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...
An AI Mental Health App Is Not a Therapist: How to Build One Honestly
It's 3am. Thoughts are racing in circles, and there is no one to talk to: friends are asleep, the next appointment with a psychotherapist is weeks away, and not everyone can afford one. So a person either lies awake, scrolls endlessly through social media, or turns to...
Weekly News Roundup | 12 October 2026
Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?
Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....
Viatris Pacira Acquisition: What the $1.65bn Deal Buys
The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...
GLP-1 Therapy: More Than Numbers on a Scale
The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.